Co-founded by CEO Patrick Short, COO Charlotte Guzzo, and CTO William Jones, Sano Genetics is at the forefront of the precision medicine revolution. The company's innovative software integrates genetic testing, recruitment, and sustained engagement, streamlining the process for precision medicine teams and hastening patient breakthroughs.

In 2023, Sano Genetics reported a remarkable 5x increase in Annual Recurring Revenue (ARR) compared to the previous year, doubled its staff to 62, and ventured into the substantial pharmaceutical market. Collaborating with four of the top 20 pharmaceutical firms, the company has begun reaping the benefits of using AI to enhance trial processes and exceed customer expectations. With the total funding now reaching $22 million, Sano Genetics plans to use the new investment to cater to the escalating demand for its offerings, further harness AI technology, and broaden its international footprint, aiming to become the go-to platform for precision trials.

Clinical trials are the backbone of modern healthcare, yet they are notoriously intricate and lengthy for both patients and the companies conducting them. Recruiting for clinical trials poses a significant challenge, with only 20% of trials attracting enough participants within the set timeframe. This delay hinders the availability of new and potentially superior treatment options for patients.

Precision medicine, which necessitates understanding patient genetics to customise drug treatments, faces even greater recruitment challenges. In such highly regulated environments, integrating cutting-edge technology into research methodologies can be daunting for large organisations, making existing solutions for patient recruitment, genetic testing, and engagement inefficient.

Sano Genetics, operating in the UK, US, Australia, and Canada, bridges the gap between patients and companies conducting clinical trials. It offers an efficient digital solution for trial management, enhancing patient access to precision medical treatments and aiding companies in swiftly bringing effective drugs to market. The platform facilitates rapid trial setup, patient recruitment through various channels including social media and healthcare providers, and manages all trial aspects like participant communication, genetic testing, results delivery, and genetic counselling. This efficiency is achieved while maintaining a focus on security and compliance.

Precision medicine represents a paradigm shift in drug development. Clinical trials using genetic data boast a 26% success rate, a significant increase from the 10% success rate of standard clinical trials. Sano Genetics is empowering this shift, enabling global companies and research institutions to conduct precision medicine trials more effectively. The platform has already supported over 20 studies, ranging from rare diseases in newborns to neurodegenerative conditions like ALS and Parkinson’s.

In December 2023, Sano Genetics launched Light The Way, a programme for families affected by ALS. This initiative offers peer support, DNA testing, genetic counselling, and education. The company aims to use the new funding to spearhead similar initiatives, leading the way in predictive and preventive genetics, ultimately accelerating the future of precision medicine.

Patrick Short, Co-Founder and CEO of Sano Genetics, said: “Precision medicine is transforming how we think about and approach healthcare, and clinical trials are the bedrock of precision drug development. In the past 12 months, we’ve scaled up our capacity to hold three times more trials than the year before and launched our first programme supporting families affected by ALS. I’m so pleased with everything the team has achieved so far and this new funding will help us to integrate LLMs and other AI tools to drive more productivity. This will help us continue our growth trajectory, particularly with the help of visionary investors like Carina Namih, who supported our seed round and is now supporting us again at Plural.”

Carina Namih, Partner at Plural, said: “Precision medicine is going to transform how healthcare is delivered but it needs seamless software tools like Sano Genetics’ to accelerate its impact. My own experience of the difficulty of running clinical trials during my time leading HelixNano helped me understand profoundly just how sorely a platform like Sano Genetics is needed. Patrick and the Sano team have made huge strides in 2023, and I am delighted to be able to continue to support the company to bring faster, more effective clinical trials.”

Charlotte Barttelot, Principal at MMC Ventures, said: "We are excited to back Sano Genetics again after leading its Series A. We continue to see the pull from biopharma for a market-leading infrastructure software to underpin their precision medicine trials which has been evidenced by the strong growth in 2023. We are excited to see this accelerate into 2024."